01
Pharma & Life Sciences
HEOR, pricing, market access and reimbursement that turn clinical and economic evidence into access for patients.
See engagementsHealth economics · Evidence · Policy
Evidence that reaches the patient.
We advise governments, development partners and life-sciences organisations on what care costs, what it is worth, and how to build and pay for it. Nine countries since 2021.
2021Established
9Countries of work
22,000+Facilities surveyed
118Referral hospitals benchmarked
Delivered for
IFC · World Bank · ADB · GIZ · KfW · PPP Agency of Ukraine · Ministries of Finance and Health · National and state health authorities · Roche · Vantive · FIND · IQVIA · Sathguru · WISH Foundation · McGill University
What we do
Four verticals, one integrated team
Health economics, evidence and policy applied across the areas where our clients work. The same analytical core, four different sets of decisions.
02
Health Infrastructure
Planning and PPP transaction advisory for new facilities. Large-scale assessment of existing ones to strengthen standards and policy.
See engagements03
Health Financing
Designing, implementing and strengthening publicly funded insurance, benefit packages, provider payment and scheme policy.
See engagements04
Climate & Health
EmergingClimate-resilient and low-carbon health systems, health-adaptation financing, and the health co-benefits of climate action.
See engagementsOur work
Named engagements, not case studies
Health Infrastructure
Post-transplant rehabilitation centre, Irpin
Feasibility study and procurement of a private operator for Ukraine's first specialised post-transplant rehabilitation centre.
Health Infrastructure
National survey of 22,000+ health facilities
A national survey of public and private facilities, 8,000 of them assessed.
Health Financing
Technical assistance to the National Health Authority, AB PM-JAY
Implementation support, and new policy, guidelines and SOPs for the world's largest publicly funded health scheme.
Pharma & Life Sciences
FinCan: equitable cancer-care coverage under AB PM-JAY
With AIIMS Delhi. Standard-of-care pathways for breast and lung cancer, cost-of-care and budget-impact modelling, and financing options to close the gap in AB PM-JAY cancer financing.
Health Infrastructure
Imaging and radiology PPP options, 12 hospitals
Assessment and PPP options across seven regional and five teaching hospitals.
Pharma & Life Sciences
Inclusion of new therapies under AB PM-JAY
Upgrading the existing package and inclusion of new therapies under AB PM-JAY, and development of packages under the Transaction Management System to enable pre-authorisations at empanelled healthcare facilities.
Where we work
Nine countries, four regions
South and Southeast Asia, MENA, Eastern Europe and West Africa. Every country here is one we have delivered in, not one we are open to.
South & Southeast Asia
India · Pakistan · Cambodia · Malaysia
MENA
Oman · Saudi Arabia
Eastern Europe
Romania · Ukraine
West Africa
Ghana
Why GGC
Why clients partner with us
Four verticals in nine countries, run so that the person who scopes your work is the person who delivers it.
- 01
Different teams across four verticals
Pharma, infrastructure, financing and climate & health, each run by a mix of senior and mid-level experts.
- 02
Public-system and policy depth
Advisory grounded in delivery, not desk-based analytics alone.
- 03
Evidence linked to implementation
We carry work from design through to delivery, rather than handing over a report and leaving.
- 04
Senior, founder-led attention
Across nine countries in Asia, MENA, Eastern Europe and West Africa.
Founder led
Every engagement runs through the partner you meet first.
I started Garnet in 2021 because too much good health economics stops at the report. A costing model matters when it changes what a scheme will pay for. A feasibility study matters when the hospital gets built. We stay with the work until it reaches that point.
Dr. Varun Goyal
Managing Partner